^
Association details:
Biomarker:No biomarker
Cancer:Renal Cell Carcinoma
Drug:Aybintio (bevacizumab biosimilar) (VEGF-A inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Source:
Title:

Samsung Bioepis acquires European sales license for anticancer drug'Abincio (SB8)'

Published date:
08/21/2020
Excerpt:
Samsung Bioepis (CEO: Han-Seung Ko) from the European Commission (EC) It was announced on the 21st that it has obtained the final marketing approval for'AYBINTIO ® , Avastin biosimilar, project name SB8, ingredient name bevacizumab' in Europe.